High expression of TACC3 in esophageal squamous cell carcinoma correlates with poor prognosis
Metrics: PDF 2368 views | HTML 2201 views | ?
Zhi-Liang Huang1,2,*, Zhi-Rui Lin1,*, Yi-Ren Xiao3, Xun Cao1,4, Lin-Chun Zhu1,2, Mu-Sheng Zeng1, Qian Zhong1, Zhe-Sheng Wen1,2
1State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
2Department of Thoracic Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China
3South China Institute for Stem Cell Biology and Regenerative Medicine Key Laboratory of Regenerative Biology, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China
4Department of Critical Care Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China
*These authors have contributed equally to this work
Qian Zhong, e-mail: [email protected]
Zhe-Sheng Wen, e-mail: [email protected]
Keywords: TACC3, Esophageal squamous carcinoma (ESCC), prognostic biomarker, immunohistochemistry
Received: December 04, 2014 Accepted: January 23, 2015 Published: February 10, 2015
To analyze the expression of the transforming acidic coiled-coil protein 3 (TACC3) in esophageal squamous cell carcinoma (ESCC) samples, and to identify whether TACC3 can serve as a biomarker for the diagnosis and prognosis of ESCC, qPCR, western blotting and immunohistochemistry staining (IHC) were utilized to detect the expression of TACC3. Furthermore, cell growth, colony formation, migration ability and the epithelial-mesenchymal transition markers of ESCC cells in which TACC3 were knocked-down were measured. The mRNA and protein levels of TACC3 were higher in ESCC specimens compared to non-tumorous esophageal epithelial tissues. IHC results revealed TACC3 expression was significantly correlated to differentiation (p = 0.017) and lymphoid nodal status (p = 0.028). The patients with high-expression of TACC3 had a significantly poor prognosis compared to those of low-expression (p = 0.017), especially in the patients at stages I–II (p = 0.028). Multivariate analysis indicated that TACC3 expression was an independent prognostic factor for ESCC patients (p = 0.025). Knockdown of TACC3 inhibited the ability of cell proliferation, colony formation and migration. This study first identifies TACC3 not only as a useful biomarker for diagnose and prognosis of ESCC, but also as a potential therapeutic target for patients with ESCC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.